XNASABOS
Market cap99mUSD
Jan 17, Last price
1.65USD
1D
2.48%
1Q
-42.31%
IPO
-91.86%
Name
Acumen Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-52m
L+29.39%
CFO
-43m
L+22.50%
Earnings
Mar 24, 2025
Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 103,456 | 45,406 | |||
Unusual Expense (Income) | |||||
NOPBT | (103,456) | (45,406) | |||
NOPBT Margin | |||||
Operating Taxes | (2,381) | ||||
Tax Rate | |||||
NOPAT | (103,456) | (43,025) | |||
Net income | (52,371) 29.39% | (40,475) -77.72% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 121,904 | 3,907 | |||
BB yield | -65.31% | -1.78% | |||
| Debt | |||||
Debt current | 1,732 | 105 | |||
Long-term debt | 28,771 | 105 | |||
Deferred revenue | |||||
Other long-term liabilities | 2,560 | ||||
Net debt | (275,572) | (193,232) | |||
| Cash flow | |||||
Cash from operating activities | (43,064) | (35,153) | |||
CAPEX | (21) | (161) | |||
Cash from investing activities | (171,671) | 39,185 | |||
Cash from financing activities | 151,753 | 3,907 | |||
FCF | (103,689) | (43,259) | |||
| Balance | |||||
Cash | 243,522 | 177,605 | |||
Long term investments | 62,553 | 15,837 | |||
Excess cash | 306,075 | 193,442 | |||
Stockholders' equity | (222,480) | (171,174) | |||
Invested Capital | 521,366 | 360,054 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 48,609 | 40,602 | |||
Price | 3.84 -28.89% | 5.40 -20.12% | |||
Market cap | 186,660 -14.86% | 219,250 -19.86% | |||
EV | (88,912) | 26,018 | |||
EBITDA | (103,272) | (45,237) | |||
EV/EBITDA | 0.86 | ||||
Interest | 2,381 | ||||
Interest/NOPBT | |||||